RT Book, Section
A1 Trujillo, Jennifer
A1 Haines, Stuart
A2 DiPiro, Joseph T.
A2 Yee, Gary C.
A2 Haines, Stuart T.
A2 Nolin, Thomas D.
A2 Ellingrod, Vicki L.
A2 Posey, L. Michael
SR Print(0)
ID 1205562736
T1 Diabetes Mellitus
T2 DiPiro’s Pharmacotherapy: A Pathophysiologic Approach, 12th Edition
YR 2023
FD 2023
PB McGraw Hill
PP New York, NY
SN 9781264264544
LK accesspharmacy.mhmedical.com/content.aspx?aid=1205562736
RD 2024/04/25
AB Update  SummaryMay,  2023The  following  sections,  tables,  and  figures  were  updated:Extensive  revisions  were  made  throughout  the  chapter  based  on  the  new  recommendations  from  the  2023  American  Diabetes  Association  Standards  of  Care  to  the  following  sections:Approach  to  treatmentStepwise  addition  of  medicationsComplications  and  comorbiditiesTirzepatide,  a  dual  glucose-like  peptide-1  (GLP-1)  and  glucose-dependent  insulinotropic  polypeptide  (GIP)  receptor  agonist,  was  approved  by  the  FDA  in  2022.  Information  regarding  tirzepatide  has  been  added  in  multiple  sections  and  Table  94-10.